Scarica l'app Stockscreener
5.89
4.54%
-0.28
Dopo l'orario di chiusura:
5.94
0.05
+0.85%
Kura Oncology Inc Borsa (KURA) Ultime notizie
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - MarketScreener
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Kura Oncology Strengthens Team: Strategic Stock Options Awarded to New Hires - Stock Titan
Kura Oncology (NASDAQ:KURA) Upgraded to “Buy” at StockNews.com - Defense World
Corient Private Wealth LLC Makes New $109,000 Investment in Kura Oncology, Inc. (NASDAQ:KURA) - Defense World
Kura Oncology, Inc. (NASDAQ:KURA) Shares Bought by Teacher Retirement System of Texas - Defense World
Kura Oncology to Participate in Stifel Targeted Oncology Forum - The Manila Times
Kura Oncology CEO Set to Reveal Latest Cancer Treatment Strategy at Elite Stifel Forum - Stock Titan
Kura Oncology stock hits 52-week low at $6.75 amid market challenges - Investing.com
Virtu Financial LLC Makes New Investment in Kura Oncology, Inc. (NASDAQ:KURA) - Defense World
Kura Oncology (NASDAQ:KURA) Shares Down 2.7%Should You Sell? - MarketBeat
Kura Oncology (NASDAQ:KURA) Upgraded by StockNews.com to Buy Rating - Defense World
Kura Oncology presents promising preclinical data By Investing.com - Investing.com South Africa
Kura Oncology presents promising preclinical data - Investing.com India
Kura Oncology Announces Preclinical Data for KO-2806 Selected for Oral Presentation at the 2025 AACR Annual Meeting - The Manila Times
Charles Schwab Investment Management Inc. Buys 10,542 Shares of Kura Oncology, Inc. (NASDAQ:KURA) - Defense World
Kura Oncology director Hasnain Faheem sells $181,456 in shares By Investing.com - Investing.com Australia
Insider Sell: Faheem Hasnain Sells 22,682 Shares of Kura Oncology Inc (KURA) - GuruFocus
Kura Oncology director Hasnain Faheem sells $181,456 in shares - Investing.com
Bank of New York Mellon Corp Decreases Stock Position in Kura Oncology, Inc. (NASDAQ:KURA) - Defense World
Brokers Issue Forecasts for Kura Oncology FY2025 Earnings - Defense World
Kura Oncology (NASDAQ:KURA) Downgraded by StockNews.com to “Hold” - Defense World
US Bancorp DE Has $193,000 Stake in Kura Oncology, Inc. (NASDAQ:KURA) - Defense World
Kura Oncology, Inc. (NASDAQ:KURA) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World
BTIG Research downgrades Kura Oncology Inc (KURA) stock to a Neutral - Knox Daily
Kura Oncology Inc (KURA) Q4 2024 Earnings: EPS of -$0.22 Beats E - GuruFocus.com
Kura Oncology at Leerink Conference: Strategic Advances in AML Therapies By Investing.com - Investing.com UK
Kura Oncology at Leerink Conference: Strategic Advances in AML Therapies - Investing.com
Kura Oncology stock hits 52-week low at $6.98 amid challenges - Investing.com Australia
Kura Oncology stock hits 52-week low at $6.98 amid challenges By Investing.com - Investing.com South Africa
Recent Research Analysts’ Ratings Changes for Kura Oncology (KURA) - Defense World
UBS Group Issues Pessimistic Forecast for Kura Oncology (NASDAQ:KURA) Stock Price - Defense World
Metrics That Matter About Kura Oncology Inc (NASDAQ: KURA) - Stocks Register
Kura Oncology's Latest Strategic Move: 190K Share Options Package Draws Top Talent - StockTitan
Kura Oncology, Inc. to Host Earnings Call - ACCESS Newswire
Kura Oncology price target lowered to $14 from $27 at UBS - TipRanks
Cantor Fitzgerald Comments on Kura Oncology FY2025 Earnings - Defense World
Kura Oncology (NASDAQ:KURA) Rating Increased to Buy at StockNews.com - Defense World
UBS Adjusts Price Target on Kura Oncology to $14 From $27, Keeps Buy Rating -March 06, 2025 at 09:52 am EST - Marketscreener.com
Kura Oncology’s SWOT analysis: ziftomenib trials key for AML stock’s future - Investing.com India
Kura Oncology’s SWOT analysis: ziftomenib trials key for AML stock’s future By Investing.com - Investing.com South Africa
Kura Oncology (NASDAQ:KURA) Raised to “Strong-Buy” at Cantor Fitzgerald - Defense World
Industry Analysts Just Upgraded Their Kura Oncology, Inc. (NASDAQ:KURA) Revenue Forecasts By 62% - Simply Wall St
Kura Oncology: The Market Sees A Tough Road Ahead, And I Think There's An Opportunity - Seeking Alpha
Brokers Issue Forecasts for Kura Oncology FY2026 Earnings - Defense World
FY2025 EPS Estimate for Kura Oncology Reduced by Analyst - Defense World
HC Wainwright Predicts Kura Oncology Q2 Earnings - Defense World
Wedbush Estimates Kura Oncology’s Q1 Earnings (NASDAQ:KURA) - Defense World
Kura Oncology’s (KURA) Outperform Rating Reiterated at Wedbush - Defense World
HC Wainwright Weighs in on Kura Oncology Q1 Earnings - Armenian Reporter
Brokers Offer Predictions for Kura Oncology Q1 Earnings - Armenian Reporter
Kura Oncology’s Financial Future at Risk: Dependency on Kyowa Kirin for Ziftomenib Development Raises Concerns - TipRanks
Research Analysts Set Expectations for Kura Oncology Q1 Earnings - MarketBeat
Equities Analysts Issue Forecasts for Kura Oncology Q1 Earnings - Defense World
10.70%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):